These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23141116)

  • 21. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].
    Hanon O; Laroche P; Vidal JS; Pannier B; Postel-Vinay N; Vaisse B; Girerd X
    Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):218-23. PubMed ID: 22695025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renin-Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study.
    Christiansen CF; Heide-Jørgensen U; Rasmussen TB; Bodilsen J; Søgaard OS; Maeng M; Vistisen ST; Schmidt M; Pottegård A; Lund LC; Reilev M; Hallas J; Johansen NB; Brun NC; Sørensen HT; Thomsen RW
    J Am Heart Assoc; 2020 Oct; 9(19):e017297. PubMed ID: 32998607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs).
    Hsieh MS; How CK; Hsieh VC; Chen PC
    Shock; 2020 Apr; 53(4):407-415. PubMed ID: 31135703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
    Dollar A; Brown C; Putnam D; McLaughlin T; Okamoto L; Arocho R
    Clin Ther; 2002 Jun; 24(6):930-41. PubMed ID: 12117083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment patterns and adherence to antihypertensive combination therapies in Japan using a claims database.
    Ishida T; Oh A; Hiroi S; Shimasaki Y; Nishigaki N; Tsuchihashi T
    Hypertens Res; 2019 Feb; 42(2):249-256. PubMed ID: 30443023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.
    Butt DA; Mamdani M; Gomes T; Lix L; Lu H; Tu K;
    J Bone Miner Res; 2014 Nov; 29(11):2483-8. PubMed ID: 24806397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
    Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
    Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia.
    Gadzhanova S; Roughead EE; Bartlett LE
    Eur J Clin Pharmacol; 2016 Jun; 72(6):765-71. PubMed ID: 26961086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
    Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
    J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
    Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
    Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
    J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.
    Kwok T; Leung J; Barrett-Connor E;
    Age Ageing; 2017 Jan; 46(1):57-64. PubMed ID: 28181652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
    Qiao Y; Shin JI; Chen TK; Inker LA; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    JAMA Intern Med; 2020 May; 180(5):718-726. PubMed ID: 32150237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R; Tonolo G
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective longitudinal cohort study comparing the effects of angiotensin-converting enzyme inhibitors and long-acting calcium channel blockers on total and cardiovascular mortality in patients with hypertension.
    Tardif JC; Ducharme A; Yu H; Wogen J; Guertin MC
    Clin Ther; 2004 Jul; 26(7):1073-83. PubMed ID: 15336472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of the effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on anemia in patients with normal or mildly low glomerular filtration rate.
    Ergün B; Aybal Kutlugün A; Ergün MÇ; Aktürk G; Beyan E
    Turk J Med Sci; 2021 Dec; 51(6):3047-3052. PubMed ID: 34519192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up.
    Jeong HS; Lim HS; Park HJ; Lee WS; Choi JO; Lee HS; Jo SH; Hong SJ
    Sci Rep; 2021 Jan; 11(1):1783. PubMed ID: 33469103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.